Imagine being denied life-saving medical treatment because you live in the wrong country. Patients’ access to the latest medicines varies greatly among EU members, and the health consequences are often grave. But the Commission’s current approach goes about it the wrong way — by cutting back on intellectual property protection for drug developers.